8-K: Paragon 28 Acquired by Zimmer Biomet: Merger Completed, Stock Delisted

Paragon 28, Inc. has completed its merger with a subsidiary of Zimmer Biomet, resulting in the company becoming a wholly-owned subsidiary and the delisting of its common stock from the New York Stock Exchange.

Summary

• Paragon 28, Inc. completed its merger with Gazelle Merger Sub I, Inc., a wholly-owned subsidiary of Zimmer, Inc. on April 21, 2025.
• As a result of the merger, Paragon 28 is now a wholly-owned subsidiary of Zimmer, Inc. and an indirect subsidiary of Zimmer Biomet Holdings, Inc.
• Each outstanding share of Paragon 28 common stock was converted into the right to receive $13.00 in cash and one contingent value right (CVR).
• The CVR entitles holders to a cash payment of up to $1.00 per CVR if Net Revenue exceeds $346 million during 2026, with the full $1.00 payable if Net Revenue reaches $361 million.
• Stock options and restricted stock units (RSUs) were also cashed out and converted into CVRs, with specific terms depending on the exercise price and vesting conditions.
• Paragon 28's common stock has been delisted from the New York Stock Exchange.
• The company terminated its Loan Agreement and Credit Agreement, repaying all outstanding obligations.
• Several directors and officers departed from the company upon completion of the merger.
• Amendments were made to the employment agreements of certain officers to provide for lump-sum severance and bonus payments.
• Letter agreements were delivered to Albert DaCosta and Chadi Chahine providing for tax reimbursement payments of $2,767,180 and $2,536,917 respectively.
• The certificate of incorporation and bylaws of the surviving corporation were amended and restated.

Sentiment

Score: 7

Explanation: The document signals a positive outcome for Paragon 28 shareholders who received a cash payment and a CVR. The sentiment is neutral to positive, reflecting the completion of a significant corporate event.

Positives

• Shareholders received $13.00 per share in cash.
• The CVR provides an opportunity for additional payment based on future performance.
• The company terminated its Loan Agreement and Credit Agreement, repaying all outstanding obligations.

Negatives

• Paragon 28 is no longer a publicly traded company.
• Shareholders no longer have equity ownership in the company.
• The CVR payment is contingent on achieving specific revenue targets, with no guarantee of payment.
• Several key executives have departed from the company.

Risks

• The CVR payment is dependent on Paragon 28 achieving specific net revenue targets in 2026, which may not be met.
• The integration of Paragon 28 into Zimmer Biomet could present challenges.
• Changes in management and strategy following the acquisition could impact the company's performance.

Future Outlook

The future performance of Paragon 28 is now tied to Zimmer Biomet's overall strategy and execution. The potential for CVR payments depends on Paragon 28's ability to achieve specific net revenue targets in 2026.

Industry Context

The acquisition of Paragon 28 by Zimmer Biomet reflects a trend of consolidation in the medical device industry, with larger companies acquiring smaller, innovative players to expand their product portfolios and market reach.

Comparison to Industry Standards

• The acquisition multiple and CVR structure are fairly standard for acquisitions of medical device companies with growth potential.
• Comparable acquisitions in the medical device space often include upfront cash payments plus contingent payments based on future performance milestones.
• The specific revenue targets for the CVR payment will need to be assessed in the context of Paragon 28's historical growth rates and the overall market conditions in the orthopedic sector.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders received cash and a potential future payment through the CVR.
• Employees may experience changes in their roles and responsibilities as a result of the acquisition.
• Customers and suppliers may see changes in the company's products, services, and business practices.

Next Steps

• Zimmer Biomet will integrate Paragon 28 into its existing operations.
• Paragon 28 will focus on achieving the net revenue targets required for CVR payments in 2026.
• The company will file a Form 15 with the SEC to terminate the registration of its common stock and suspend reporting obligations.

Key Dates

Keywords

merger, acquisition, Zimmer Biomet, Paragon 28, CVR, delisting, net revenue